| 9.46 -0.21 (-2.17%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.84 | 1-year : | 15 |
| Resists | First : | 11 | Second : | 12.84 |
| Pivot price | 9.89 |
|||
| Supports | First : | 7.76 | Second : | 5.76 |
| MAs | MA(5) : | 9.95 |
MA(20) : | 9.67 |
| MA(100) : | 7.5 |
MA(250) : | 8.42 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 46.8 |
D(3) : | 58.6 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 14.56 | Low : | 5.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RNAC ] has closed above bottom band by 25.4%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.75 - 9.8 | 9.8 - 9.86 |
| Low: | 9.06 - 9.12 | 9.12 - 9.18 |
| Close: | 9.35 - 9.45 | 9.45 - 9.57 |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Thu, 02 Jul 2026
Cartesian offers 8 new hires stock options worth 238,700 shares - Stock Titan
Thu, 02 Jul 2026
Cartesian Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Mon, 29 Jun 2026
RNAC - Cartesian Therapeutics Inc Latest SEC Filings - Finviz
Fri, 26 Jun 2026
RNAC Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 26 Jun 2026
Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC) - TradingView
Fri, 12 Jun 2026
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 1.063e+007 (%) |
| Held by Institutions | 53.6 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.89e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -33 % |
| Return on Assets (ttm) | 973 % |
| Return on Equity (ttm) | -16.4 % |
| Qtrly Rev. Growth | 1.77e+006 % |
| Gross Profit (p.s.) | -119.11 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.82692e+007 |
| Qtrly Earnings Growth | -5.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.43 |
| Dividend | 0 |
| Forward Dividend | 1.93e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|